Ceftriaxone for Salmonella Infection
Ceftriaxone is indicated for Salmonella infection, but its use depends critically on the type of Salmonella and patient risk factors. For typhoidal Salmonella (S. Typhi and S. Paratyphi), ceftriaxone is a first-line agent, while for nontyphoidal Salmonella, it is reserved for high-risk patients or when susceptibility is confirmed 1.
Typhoidal Salmonella (S. Typhi and S. Paratyphi)
Ceftriaxone is a first-line treatment option alongside ciprofloxacin for typhoid and paratyphoid fever 1. The IDSA guidelines explicitly list ceftriaxone as a primary choice for these infections, with alternatives including ampicillin, TMP-SMX, or azithromycin 1.
- Historical data demonstrates excellent efficacy, with cure rates of 23/25 (92%) for ceftriaxone in typhoid/paratyphoid fever, and a relapse rate of only 4% 2
- The FDA label confirms ceftriaxone is indicated for bacterial septicemia and meningitis caused by susceptible organisms, which includes Salmonella species 3
Important caveat: Emerging resistance to ceftriaxone in typhoidal Salmonella has been documented in South Asia, including Pakistan and India, with isolates carrying blaCTX-M-15, blaSHV-12, and other ESBL genes 4, 5. This makes susceptibility testing essential before or during treatment.
Nontyphoidal Salmonella
For uncomplicated nontyphoidal Salmonella gastroenteritis, antimicrobial therapy is usually NOT indicated 1. Treatment can paradoxically prolong fecal shedding and does not improve outcomes in healthy individuals.
When Ceftriaxone IS Indicated for Nontyphoidal Salmonella:
Antimicrobial therapy with ceftriaxone should be considered for high-risk groups at increased risk for invasive infection 1:
- Neonates (up to 3 months old) 1
- Persons >50 years old with suspected atherosclerosis 1
- Immunosuppressed patients 1
- Cardiac disease (valvular or endovascular) 1
- Significant joint disease 1
If treatment is warranted and the organism is susceptible, ceftriaxone is one of several acceptable options alongside ciprofloxacin, TMP-SMX, or amoxicillin 1.
Clinical Evidence for Severe Cases:
- Short-course ceftriaxone therapy (3-5 days at 50 mg/kg/day) demonstrated rapid defervescence in pediatric patients with severe nontyphoidal Salmonella enterocolitis (bloody/mucoid diarrhea with high fever >48 hours and moderate-to-severe dehydration), with no relapses observed 6
- A 5-year Italian surveillance study showed ceftriaxone was effective in vivo in all 56 children requiring antibiotic therapy, with only 1.8% resistance rate among isolates 7
Resistance Concerns
Ceftriaxone resistance in Salmonella is increasing globally and represents a significant public health threat, particularly in pediatric populations where fluoroquinolones are not approved 8, 9.
- Among pediatric isolates in China, 53/205 (25.9%) were ceftriaxone-resistant, with 50/53 occurring in children <4 years old 9
- CTX-M-type ESBLs (particularly CTX-M-55, CTX-M-65, and CTX-M-14) are the predominant resistance mechanisms, often plasmid-mediated 9, 5
- A recent systematic review (2025) found azithromycin and ceftriaxone were more effective than other agents based on hospital length of stay and fever resolution, though azithromycin showed less resistance development 10
Practical Algorithm
- Identify Salmonella type: Typhoidal vs. nontyphoidal
- For typhoidal Salmonella: Use ceftriaxone as first-line (or ciprofloxacin), obtain susceptibility testing given emerging resistance 1, 4
- For nontyphoidal Salmonella:
- Always obtain susceptibility testing when treatment is indicated, as resistance rates vary geographically 7, 9
Common pitfall: Treating uncomplicated nontyphoidal Salmonella gastroenteritis in immunocompetent patients can prolong carrier state without clinical benefit 1. Reserve treatment for truly high-risk or invasive disease.